Are Anti-β2 Glycoprotein 1 Antibodies Associated with Placenta-Mediated Pregnancy Complications? A Nested Case–Control Study

Leslie Skeith; Karim E. Abou-Nassar; Mark Walker; Tim Ramsay; Ronald Booth; Shi Wu Wen; Graeme N. Smith; Marc A. Rodger

doi:10.1055/s-0038-1641168

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2018; 35(11): 1093-1099
DOI: 10.1055/s-0038-1641168

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Are Anti-β2 Glycoprotein 1 Antibodies Associated with Placenta-Mediated Pregnancy Complications? A Nested Case–Control Study

Leslie Skeith

¹Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

²Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

,

Karim E. Abou-Nassar

³Service d'Hématologie et Axe de Recherche en Cancérologie, Centre Intégré de Santé et de Services Sociaux de l'Outaouais, Gatineau, Quebec, Canada

,

Mark Walker

²Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

⁴Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, Canada

,

Tim Ramsay

²Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

,

Ronald Booth

²Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

,

Shi Wu Wen

²Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

⁴Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, Canada

,

Graeme N. Smith

⁵Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada

,

Marc A. Rodger

²Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

⁴Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, Canada

⁶Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

› Institutsangaben

Abstract

Background While anti-β2 glycoprotein 1 (anti-β2GP1) antibody positivity is included in the diagnostic criteria for antiphospholipid syndrome (APS), the association between anti-β2GP1 and the obstetrical complications of APS has been inconsistently reported and remains unclear.

Objective We completed a case–control study nested within the Canadian Ottawa and Kingston (OaK) Birth Cohort to evaluate the association between anti-β2GP1 antibody positivity and placenta-mediated pregnancy complications.

Study Design Five hundred cases were randomly selected among pregnant women who experienced any of the following independently adjudicated placenta-mediated pregnancy complications: preeclampsia, placental abruption, late pregnancy loss (≥ 12 weeks' gestation), and birth of a small-for-gestational age (SGA) infant < 10th percentile. Five hundred pregnant women without any placenta-mediated pregnancy complications were selected as controls. Stored blood samples were analyzed for the presence of anti-β2GP1 antibodies by enzyme-linked immunosorbent assay.

Results Anti-β2GP1 immunoglobulin G (IgG) and/or immunoglobulin M (IgM) antibodies in titers ≥ 20 G/M units (> 99th percentile) were present in 24 of 497 (4.8%) of controls and 33 of 503 (6.6%) of cases. There was no significant difference between cases and controls for the composite outcome of any placenta-mediated pregnancy complications (odds ratio, 1.38, 95% confidence interval [CI], 0.8–2.37, p = 0.25).

Conclusion Our results call into question the association between anti-β2GP1 antibodies and placenta-mediated pregnancy complications, with further research needed.

Keywords

antiphospholipid antibodies - antiphospholipid syndrome - pregnancy complications - placenta diseases - pregnancy outcome

Volltext

Referenzen

References
1 Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011; 128 (01) 77-85
2 Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost 2016; 14 (04) 675-684
3 Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G. , et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123 (03) 404-413
4 Yelnik CM, Laskin CA, Porter TF. , et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016; 3 (01) e000131
5 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
6 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368 (11) 1033-1044
7 Hossain N, Paidas MJ. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin Perinatol 2007; 31 (04) 208-212
8 Chaturvedi S, McCrae KR. The antiphospholipid syndrome: still an enigma. Hematology (Am Soc Hematol Educ Program) 2015; 2015: 53-60
9 Redecha P, Tilley R, Tencati M. , et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110 (07) 2423-2431
10 Katano K, Aoki A, Sasa H, Ogasawara M, Matsuura E, Yagami Y. beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11 (03) 509-512
11 Faden D, Tincani A, Tanzi P. , et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correiation with pregnancy outcome. Anti-B2 glycoprotein I antibodies are associated with some obstetrical complications, mainly pre-eclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 73 (01) 37-42
12 Lee RM, Emlen W, Scott JR, Branch DW, Silver RM. Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. Am J Obstet Gynecol 1999; 181 (03) 642-648
13 Valdés-Macho E, Cabiedes J, Villa AR, Cabral AR, Alarcón-Segovia D. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy. Arch Med Res 2002; 33 (05) 460-465
14 Lee RM, Brown MA, Branch DW, Ward K, Silver RM. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol 2003; 102 (02) 294-300
15 Vora S, Shetty S, Salvi V, Satoskar P, Ghosh K. A comprehensive screening analysis of antiphospholipid antibodies in Indian women with fetal loss. Eur J Obstet Gynecol Reprod Biol 2008; 137 (02) 136-140
16 Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A. , et al; (EUROAPS Study Group Collaborators). The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 2015; 14 (05) 387-395
17 Silver RM, Parker CB, Reddy UM. , et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol 2013; 122 (03) 641-657
18 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e691S-e736S
19 Walker MC, Finkelstein SA, Rennicks White R. , et al. The Ottawa and Kingston (OaK) Birth Cohort: development and achievements. J Obstet Gynaecol Can 2011; 33 (11) 1124-1133
20 Rodger MA, Walker MC, Smith GN. , et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost 2014; 12 (04) 469-478
21 Kramer MS, Platt RW, Wen SW. , et al; Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001; 108 (02) E35
22 Ferrer-Oliveras R, Llurba E, Cabero-Roura L, Alijotas-Reig J. Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets. Lupus 2012; 21 (03) 257-263
23 Lockshin MD, Kim M, Laskin CA. , et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64 (07) 2311-2318
24 Yelnik CM, Porter TF, Branch DW. , et al. Brief Report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes. Arthritis Rheumatol 2016; 68 (08) 1964-1969
25 Ruffatti A, Tonello M, Visentin MS. , et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011; 50 (09) 1684-1689
26 de Laat B, Pengo V, Pabinger I. , et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7 (11) 1767-1773
27 Yamada H, Atsumi T, Kobashi G. , et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009; 79 (02) 188-195